Factbox-Global drugmakers rush to boost US presence as tariff threat looms
(Reuters) -Global drugmakers are scrambling to shore up their U.S. manufacturing capacity and domestic inventory as the Trump administration moves ahead with a 100% tariff on imported branded and patented drugs, starting October 1.The sweeping measure has triggered a flurry of activity across the industry, including fast-tracking U.S. manufacturing projects, price cuts and direct-to-consumer sales.Here's what drugmakers are doing to mitigate supply-chain risks and reassure investors:PfizerPfizer reached a deal with President Donald Trump on September 30 to invest $70 billion in research and de…